Plasma Proteomics Framework Predicts Metabolic Dysfunction-Associated Steatotic Liver Disease Up to 16 Years Before Onset

Metabolic dysfunction-associated steatotic liver disease (MASLD) is a significant global health challenge. However, preclinical identification remains difficult due to the lack of reliable predictive tools. A recent study published in [insert journal name] demonstrates that a panel of five plasma proteins can serve as a predictive signature for incident MASLD. The authors identified and validated this five-protein model across over 50,000 participants from various cohorts, including the Southern UK, Northern UK, EPIC-Norfolk, and Southern China cohorts. The model achieved high predictive accuracy, with an area under the curve (AUC) of 0.838 for a 5-year prediction period and 0.756 for a 16.6-year prediction period. Longitudinal performance was sustained in the EPIC-Norfolk cohort, while the Southern China Inception Cohort confirmed these findings. Integrating these biomarkers with routine clinical data further enhanced performance. These results establish a scalable proteomic framework for ultra-early risk stratification and targeted intervention in MASLD up to 16 years before clinical onset. However, it is essential to note that this study was conducted using research-use-only peptides and should not be used for clinical diagnosis or treatment without proper validation and regulatory approval.